cGAS-STING Pathway Targeted Therapies and Their Applications in the Treatment of High-Grade Glioma

Authors

Shashwat Tripathi
Hinda Najem
Akanksha Sanjay Mahajan
Peng Zhang
Justin T Low
Alexander H Stegh
Michael A Curran
David M Ashley
Charles David James
Amy B Heimberger

Publication Date

1-1-2022

Journal

F1000Research

Abstract

Median survival of patients with glioblastoma (GBM) treated with standard of care which consists of maximal safe resection of the contrast-enhancing portion of the tumor followed by radiation therapy with concomitant adjuvant temozolomide (TMZ) remains 15 months. The tumor microenvironment (TME) is known to contain immune suppressive myeloid cells with minimal effector T cell infiltration. Stimulator of interferon genes (STING) is an important activator of immune response and results in production of Type 1 interferon and antigen presentation by myeloid cells. This review will discuss important developments in STING agonists, potential biomarkers for STING response, and new combinatorial therapeutic approaches in gliomas.

Keywords

Humans, Glioma, Interferons, Membrane Proteins, Nucleotidyltransferases, Tumor Microenvironment, glioblastoma, cGAS-STING, STING Agonist, immune therapies, tumor microenvironment, immune cells, myeloid cells, T cells, glioblastoma, cGAS-STING, STING Agonist, immune therapies, tumor microenvironment, immune cells, myeloid cells, T cells

DOI

10.12688/f1000research.125163.1

PMID

36324813

PMCID

PMC9597127

PubMedCentral® Posted Date

9-7-2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes